Oyinkan Penny, NP
Family · Kansas City, MONPI 1417231796
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Pfizer at 37.6% of the total. 2025 is the largest year on record at $11,951, more than ten times the $326 reported in 2021. Among family clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 156 payments — averaging $231.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$14K
- Evoke Pharma, Inc.$9K
- Eli Lilly$5K
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Novo Nordisk$949
- plus $3K from 18 others
What the payments were for
- Consulting fees$4,83013%
- Speaking & faculty fees$13,50037%
- Travel & lodging$8,58824%
- Food & beverage$9,17125%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 18 | $13,587 |
| Evoke Pharma, Inc. | 8 | $9,239 |
| Eli Lilly | 10 | $4,699 |
| AbbVie | 52 | $3,329 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $1,426 |
| Novo Nordisk | 2 | $949 |
| Johnson & Johnson | 10 | $502 |
| Ardelyx, Inc. | 8 | $470 |
| Lilly USA, LLC | 5 | $277 |
| Madrigal Pharmaceuticals | 4 | $210 |
| Janssen Scientific Affairs, LLC | 2 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $174 |
| Aimmune Therapeutics, Inc. | 3 | $164 |
| Mirum Pharmaceuticals, Inc. | 1 | $124 |
| QOL Medical, LLC | 1 | $123 |
| Axsome Therapeutics, Inc. | 1 | $120 |
| Ipsen Biopharmaceuticals, Inc | 2 | $117 |
| E.r. Squibb & Sons, L.L.C. | 1 | $100 |
| Exact Sciences | 1 | $82 |
| Regeneron Healthcare Solutions, Inc. | 2 | $69 |
| Celltrion USA Inc. | 3 | $63 |
| Phathom Pharmaceuticals, Inc. | 1 | $41 |
| Intercept Pharmaceuticals, Inc. | 1 | $18 |
| Mylan Institutional Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,090 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family in Kansas City
- Shayla SandersKansas City$306K
- Goldie BenzKansas City$27K
- Lucy Carter ReardonKansas City$25K
- Lyla MastersKansas City$22K
- Donna McCurryKansas City$20K
- Mary Zahau LoehnerKansas City$20K
- Cherie NydeggerKansas City$17K
- Charity SlaytonKansas City$17K
- Samantha IrwinKansas City$17K
- Christen CraigKansas City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.